Insider Trading Activity United Therapeutics Corporation (NASDAQ:UTHR) – CEO Sold 2,176 shares of Stock

0

Insider Trading Activity For United Therapeutics Corporation (NASDAQ:UTHR)

Martine A Rothblatt , CEO of United Therapeutics Corporation (NASDAQ:UTHR) reportedly Sold 2,176 shares of the company’s stock at an average price of 127.11 for a total transaction amount of $276,591.36 SEC Form

Insider Trading History For United Therapeutics Corporation (NASDAQ:UTHR)

  • On 9/5/2012 Christopher Patusky, Director, sold 2,000 with an average share price of $55.47 per share and the total transaction amounting to $110,940.00.View SEC Filing
  • On 9/6/2012 Christopher Causey, Director, sold 1,500 with an average share price of $55.94 per share and the total transaction amounting to $83,910.00.View SEC Filing
  • On 10/4/2012 Paul A Mahon, EVP, sold 6,000 with an average share price of $38.00 per share and the total transaction amounting to $228,000.00.View SEC Filing
  • On 10/4/2012 John Maxim Ferrari, CFO, sold 1,550 with an average share price of $58.00 per share and the total transaction amounting to $89,900.00.View SEC Filing
  • On 10/4/2012 Christopher Causey, Director, sold 1,500 with an average share price of $58.33 per share and the total transaction amounting to $87,495.00.View SEC Filing
  • On 11/26/2012 Christopher Causey, Director, sold 1,500 with an average share price of $53.33 per share and the total transaction amounting to $79,995.00.View SEC Filing
  • On 12/21/2012 Martine A Rothblatt, CEO, bought 9,000 with an average share price of $51.85 per share and the total transaction amounting to $466,650.00.View SEC Filing
  • Analyst Ratings For United Therapeutics Corporation (NASDAQ:UTHR)
    These are 3 Sell Ratings, 7 Hold Ratings, 2 Buy Ratings .
    The current consensus rating for United Therapeutics Corporation (NASDAQ:UTHR) is Hold (Score: 1.92) with a consensus target price of $134.70 , a potential (5.05% upside)

    Analyst Ratings History For United Therapeutics Corporation (NASDAQ:UTHR)

    • On 4/11/2016 Royal Bank Of Canada Reiterated Rating Sector Perform with a price target of $150.00 to $122.00
    • On 8/23/2016 Argus Reiterated Rating Hold
    • On 11/29/2016 Barclays PLC Downgraded rating Equal Weight to Underweight with a price target of $115.00 to $100.00
    • On 1/19/2017 Standpoint Research Downgraded rating Buy to Hold
    • On 2/23/2017 Leerink Swann Boost Price Target of rating Market Perform with a price target of $127.00 to $148.00
    • On 2/23/2017 Ladenburg Thalmann Financial Services Downgraded rating Buy to Neutral with a price target of $145.00
    • On 4/3/2017 Credit Suisse Group Reiterated Rating Underperform with a price target of $120.00

    Recent Trading Activity for United Therapeutics Corporation (NASDAQ:UTHR)
    Shares of United Therapeutics Corporation closed the previous trading session at 128.23 up +1.21 0.95% with 711,369 shares trading hands.

    An ad to help with our costs